Scarica l'app Stockscreener
37.06
5.76%
2.02
Dopo l'orario di chiusura:
37.09
0.03
+0.08%
Maplight Therapeutics Inc Borsa (MPLT) Ultime notizie
MPLTMapLight Therapeutics Inc Options - Finviz
MapLight Therapeutics autism drug shows mixed potential in adolescents - MSN
Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR Readout - TipRanks
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout? - Yahoo Finance
Number of shareholders of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Price to book forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Price to earnings forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Enterprise value to EBITDA forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Price to sales forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Raymond James Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $46 - Moomoo
Maplight Therapeutics (MPLT) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
MPLT Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 MapLight Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
MapLight Therapeutics, Inc. Actuals & Estimates (NASDAQ:MPLT) - TradingView
Tonix, MapLight are new strong buys at Raymond James on upcoming catalysts - MSN
MapLight Therapeutics: The Cobenfy Challenger Does Not Look Like A Bargain (NASDAQ:MPLT) - Seeking Alpha
Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts - Seeking Alpha
MPLT Initiated Coverage On by Raymond James -- Strong Buy Rating - GuruFocus
MapLight Therapeutics Initiated at Strong Buy by Raymond James - Moomoo
Raymond James initiates MapLight stock with strong buy on drug trial - Investing.com Canada
MapLight Therapeutics, Inc. 2026 Annual Meeting Results and Company Information – SEC 8-K Filing Summary - Minichart
MapLight Therapeutics appoints two directors to board - Investing.com
MapLight Therapeutics appoints two directors to board By Investing.com - Investing.com India
MapLight Shareholders Back Board Slate and Auditor - TipRanks
MapLight Therapeutics Announces Changes to Board of Directors - The Manila Times
MapLight Therapeutics Appointed Martin Babler, Troy Cox to Bd >MPLT - Moomoo
MPLT Maintained by Craig-Hallum -- Price Target Lowered to $40 - GuruFocus
Analyst Maintains Buy/Outperform on ML-004’s Safety, Irritability Signal and Pipeline Strength; Price Target Steady at $45 - TipRanks
Overweight Rating Reaffirmed on ML004’s Irritability Efficacy and Safety Profile; $34 Price Target Maintained - TipRanks
MapLight Therapeutics stock maintained at Buy by H.C. Wainwright - Investing.com Australia
MPLT Maintained by Needham -- Price Target Raised to $42.00 - GuruFocus
Why is MapLight Therapeutics stock rallying today? - Investing.com
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents - Sahm
Form 144 MAPLIGHT THERAPEUTICS For: 10 February - Investing.com
MapLight reports Phase 2 autism trial results for ML-004 - grafa.com
Why is MapLight Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Form 8K MapLight Therapeutics Inc For: 22 June - Investing.com UK
MapLight Reports Phase 2 Data for Autism Candidate - TipRanks
MapLight’s autism drug trial misses primary endpoint By Investing.com - Investing.com Australia
H.C. Wainwright reiterates MapLight Therapeutics stock rating on muscarinic mechanism potential - Investing.com Canada
MapLight Therapeutics' Phase 2 Trial of ML-004 in Autism Spectrum Disorder Fails to Meet Primary Endpoint - Moomoo
MapLight’s autism drug trial misses primary endpoint - Investing.com
Form 8K MapLight Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Strong adolescent irritability signal in MapLight (MPLT) ML-004 Phase 2 IRIS trial - Stock Titan
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder - The Manila Times
MapLight Therapeutics, Inc.(NasdaqGS:MPLT) added to S&P Biotechnology Select Industry Index - marketscreener.com
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):